Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.65 |
| ▸ | JAK3 | P52333 | 20/20 | 0.65 |
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 11/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341690 | 1.00 | JAK1 (0.65) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL339748 | 0.94 | JAK1 (0.62) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL29610043 | 0.94 | JAK1 (0.62) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL340038 | 0.89 | JAK1 (0.67) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL29609626 | 0.89 | JAK1 (0.67) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL29610355 | 0.87 | JAK1 (0.71) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL340638 | 0.87 | JAK1 (0.71) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL339846 | 0.84 | JAK1 (0.78) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL15390067 | 0.84 | JAK1 (0.64) | JAK1JAK3SYKJAK2CYP3A4 | |
| SCHEMBL341097 | 0.83 | JAK1 (0.73) | JAK1JAK3SYKJAK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |